Gut-brain neuropeptides in the regulation of ingestive behaviors and obesity: CME

American Journal of Gastroenterology

Volumn 101, Issue 12, 2006, Pages 2848-2856

  Crowell, Michael D ^a   Decker, G Anton ^a   Levy, Rona ^b   Jeffrey, Robert ^c   Talley, Nicholas J ^d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GROWTH HORMONE SECRETAGOGUE RECEPTOR; METFORMIN; NEUROPEPTIDE; PEPTIDE YY; UROCORTIN;

BARIATRIC SURGERY; BEHAVIOR; DRUG EFFECT; ENERGY BALANCE; GASTRIC BANDING; GASTROINTESTINAL TRACT FUNCTION; GASTROPLASTY; HEALTH CARE COST; HOMEOSTASIS; HUMAN; MORBIDITY; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; STOMACH BYPASS; UNITED STATES; WEIGHT REDUCTION;

BRAIN; EATING; HUMANS; INTESTINES; NEUROPEPTIDES; OBESITY;

EID: 33845447217     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00832.x     Document Type: Review

References (94)

1. Flegal KM, Graubard BI, Williamson DF, et al. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005;293:1861-7.
2. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
3. Raebel MA, Malone DC, Conner DA, et al. Health services use and health care costs of obese and non-obese individuals. Arch Intern Med 2004;164:2135-40.
4. Strader AD, Woods SC. Gastrointestinal hormones and food intake. Gastroenterology 2005;128:175-91.
5. Delgado-Aros S, Locke GR 3rd, Camilleri M, et al. Obesity is associated with increased risk of gastrointestinal symptoms: A population-based study. Am J Gastroenterol 2004;99:1801-6.
6. Talley NJ, Quan C, Jones MP, et al. Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort. Neurogastroenterol Motil 2004;16:413-9.
7. Druce MR, Small CJ, Bloom SR. Minireview: Gut peptides regulating satiety. Endocrinology 2004;145:2660-5.
8. Flegal K, Carroll M, Ogden C, et al. Prevalence and trends in obesity among US adults, 1900-2000. JAMA 2002;288:1723-7.
9. Callaway CW. Obesity. Public Health Rep 1987;105(suppl 4):26-9.
10. National Task Force on the prevention and treatment of obesity. Overweight, obesity, and health risk. Arch Intern Med 2000;160:898-904.
11. Talley NJ, Howell S, Poulton R, et al. Obesity and chronic gastrointestinal tract symptoms in young adults: A birth cohort study. Am J Gastroenterol 2004;99:1807-14.
12. Delgado-Aros S, Locke GR, 3rd, Camilleri M, et al. Obesity is associated with increased risk of gastrointestinal symptoms: A population-based study. Am J Gastroenterol 2004;99:1801-6.
13. Levy RL, Linde JA, Feld KA, et al. The association of gastrointestinal symptoms with weight, diet, and exercise in weight-loss program participants. Clin Gastroenterol Hepatol 2005;3:992-6.
14. Loro ADJ, Orleans CS. Binge eating in obesity: Preliminary findings and guidelines for behavioral analysis and treatment. Addict Behav 1981;6:155-6.
15. Crowell MD, Cheskin LJ, Musial F. Prevalence of gastrointestinal symptoms in obese and normal weight binge eaters. Am J Gastroenterol 1994;89:387-91.
16. Pieramico O, Malfertheiner P, Nelson DK, et al. Interdigestive gastroduodenal motility and cycling of putative regulatory hormones in severe obesity. Scand J Gastroenterol 1992;27:538-44.
17. Wisen O, Hellstrom PM. Gastrointestinal motility in obesity. J Intern Med 1995;237:411-8.
18. Wisen O, Johansson C. Gastrointestinal function in obesity: Motility, secretion, and absorption following a liquid test meal. Metabolism 1992;41:390-5.
19. Wright RA, Krinsky S, Fleeman C, et al. Gastric emptying and obesity. Gastroenterology 1983;84:747-51.
20. Zahorska-Markiewicz B, Jonderko K, Lelek A, et al. Gastric emptying in obesity. Hum Nutr Clin Nutr 1986;40:309-13.
21. Horowitz M, Collins PJ, Cook DJ, et al. Abnormalities of gastric emptying in obese patients. Int J Obes Relat Metab Disord 1983;7:415-21.
22. Horowitz M, Collins PJ, Shearman DJ. Effects of increasing the caloric/osmotic content of the liquid component of a mixed solid and liquid meal on gastric emptying in obese subjects. Hum Nutr Clin Nutr 1986;40:51-6.
23. Maddox A, Horowitz M, Wishart J, et al. Gastric and esophageal emptying in obesity. Scand J Gastroenterol 1989;24:593-8.
24. Sasaki H, Nagulesparan M, Dubois A. Hypergastrinemia in obese noninsulin-dependent diabetes: A possible reflection of high prevalence of vagal dysfunction. J Clin Endocrinol Metab 1983;56:744-50.
25. Barkin JS, Reiner DK, Goldberg RI, et al. The effects of morbid obesity and the Garren-Edwards gastric bubble on solid phase gastric emptying. Am J Gastroenterol 1988;83:1364-7.
26. French SJ, Murray B, Rumsey RD, et al. Preliminary studies on the gastrointestinal responses to fatty meals in obese people. Int J Obes Relat Metab Disord 1993;17:295-300.
27. Verdich C, Madsen JL, Toubro S, et al. Effect of obesity and major weight reduction on gastric emptying. Int J Obes Metab Disord 2000;24:899-905.
28. Granstrom L, Backman L. Stomach distension in extremely obese and in normal subjects. Acta Chir Scand 1985;151:367-70.
29. Geliebter A, Schachter S, Lohmann-Walter C, et al. Reduced stomach capacity in obese subjects after dieting. Am J Clin Nutr 1996;63:170-3.
30. Geliebter A. Gastric distension and gastric capacity in relation to food intake in humans. Physiol Behav 1988;44:665-8.
31. Azpiroz F, Malagelada JR. Isobaric intestinal distension in humans: Sensorial relay and reflex gastric relaxation. Am J Physiol 1990;258:G202-7.
32. Kuiken SD, Samsom M, Camilleri M, et al. Development of a test to measure gastric accommodation in humans. Am J Physiol 1999;277:G1217-21.
33. Delgado-Aros SA, Cremonini FA, Castillo JA, et al. Independent influences of body mass and gastric volumes on satiation in humans. Gastroenterology 2004;126:432-40.
34. Klatt S, PIeramico O, Guthner C, et al. Proximal gastric motility functions are normal in severe obesity. Digestion 1997;58:115-9.
35. Stacher G. Effects of cholecystokinin and caerulein on human eating behavior and pain sensation: A review. Psychoneuroendocrinology 1986;11:39-48.
36. Moran TH, Kornbluh R, Moore K, et al. Cholecystokinin inhibits gastric emptying and contracts the pyloric sphincter in rats by interacting with low affinity CCK receptor sites. Regul Pept 1994;52:165-72.
37. Stacher G. Satiety effects of cholecytokinin and ceruletide in lean and obese man. Ann N Y Acad Sci 1985;448:431-6.
38. Smith GP, Gibbs J. Role of CCK in satiety and appetite control. Clin Neuropharmacol 1992;15(suppl 1):476A.
39. Moos AB, McLaughlin CL, Baile CA. Effects of CCK on gastrointestinal function in lean and obese Zucker rats. Peptides 1982;3:619-22.
40. Smith GP, Gibbs J. Gut peptides and the control of meal size in humans. Clin Neuropharmacol 1992;15(suppl 1):703A.
41. Stacher G, Steinringer H, Schmierer G, et al. Cholecystokinin octapeptide decreases intake of solid food in man. Peptides 1982;3:133-6.
42. Pi-Sunyer X, Kissileff HR, Thornton J, et al. C-terminal octapeptide of cholescystokinin decreases food intake in obese men. Physiol Behav 1982;29:627-30.
43. Beglinger C, Degen L, Matzinger D, et al. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am J Physiol Regul Integr Comp Physiol 2001;280:R1149-54.
44. Lloyd KC, Maxwell V, Kovacs TO, et al. Cholecystokinin receptor antagonist MK-329 blocks intestinal fat-induced inhibition of meal-stimulated gastric acid secretion. Gastroenterology 1992;102:131-8.
45. Ludtke FE, Golenhofen K, Kohne C. Direct effects of cholecystokinin on human gastric motility. Digestion 1988;39:210-8.
46. Smith GP. The therapeutic potential of cholecystokinin. Int J Obes 1984;8:35-8.
47. Toshinai K, Mondal MS, Nakazato M, et al. Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem Biophys Res Commun 2001;281:1220-5.
48. Yoshihara F, Kojima M, Hosoda H, et al. Ghrelin: A novel peptide for growth hormone release and feeding regulation. Curr Opin Clin Nutr Metal Care 2002;5:391-5.
49. Trudel L, Tomasetto C, Rio MC, et al. Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am J Physiol Gastrointest Liver Physiol 2002;282:G948-52.
50. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50:1714-9.
51. English PJ, Ghatei MA, Malik IA, et al. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 2002;87:2984-7.
52. Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 2003;138:389-96.
53. Naveilhan P, Hassani H, Canals JM, et al. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat Med 1999;5:1188-93.
54. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650-4.
55. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719-25.
56. Schirra J, Houck P, Wank U, et al. Effects of glucagon-like peptide-1 (7-36) amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 2000;46:622-31.
57. Naslund E, Gryback P, Backman L, et al. Distal small bowel hormones: Correlation with fasting antoduodenal motility and gastric emptying. Dig Dis Sci 1998;43:945-52.
58. Ranganath LR, Beety JM, Morgan LM, et al. Attenuated GLP-1 secretion in obesity: Cause or consequence? Gut 1996;38:916-9.
59. Verdich C, Toubro S, Bruemann B, et al. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001;25:1206-14.
60. Meier JJ, Gallwitz B, Schmidt WE, et al. Glucagon-like peptide 1 as a regulator of food intake and body weight: Therapeutic perspective. Eur J Pharmacol 2002;440:269-79.
61. Tang CM, Vrang N, Larson PJ. Glucagon-like peptide containing pathways in the regulation of feeding behavior. Int J Obes Relat Metab Disord 2001;25:S42-7.
62. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-20.
63. Rossner S, Hellstrom PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 1998;68:525-30.
64. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999;23:304-11.
65. Long SJ, Sutton JA, Armace WB, et al. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man. Br J Nutr 1999;81:273-9.
66. Gutzweller JP, Goke B, Drewe J, et al. Glucagon-like peptide-1: A potent regulator of food intake in humans. Gut 1999;44:81-6.
67. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide 1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999;276:R1541-4.
68. Flint A, Raben A, Ersboll AK, et al. The effect of glucagon-like peptide-1 on appetite, gastric emptying and substrate metabolism. Int J Obes Relat Metab Disord 2001;25:781-92.
69. Bailey CJ, Turner RC. Metformin [see comment]. N Engl J Med 1996;334:574-9.
70. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998;6:47-53.
71. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects [see comment]. Diabetes Care 2001;24:489-94.
72. Yasuda N, Inoue T, Nagakura T, et al. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats. J Pharmacol Exp Ther 2004;310:614-9.
73. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci 2000;66:91-103.
74. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002;8:738-42.
75. Meier JJ, Goetze O, Anstipp J, et al. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab 2004;286:E621-5.
76. Richard D, Huang Q, Timofeeva E. The corticotropin-releasing hormone system in the regulation of energy balance in obesity. Int J Obes Relat Metab Disord 2000;24:S36-9.
77. Martinez V, Wang L, Rivier JE, et al. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: Role of CRF receptor subtypes I and 2. Pharmacol Exp Ther 2003;301:611-7.
78. Million M, Maillot C, Saunders P, et al. Human urocortin II, a new CRF-related peptide, displays selective CRF92)-mediated action on gastric transit in rates. Am J Physiol Gastrointest Liver Physiol 2002;282:G34-40.
79. Seres J, Bornstein SR, Seres P, et al. Corticotropin-releasing hormone system in human adipose tissue. J Clin Endocrinol Metab 2004;89:965-70.
80. Richard D, Lin Q, Timofeeva E. The corticotropin-releasing factor family of peptides and CRF receptors: Their roles in the regulation of energy balance. Eur J Pharmacol 2002;440:189-97.
81. Asakawa A, Inui A, Ueno N, et al. Urocortin reduces food intake and gastric emptying in lean and ob/ob obese mice. Gastoenterology 1999;116:1287-92.
82. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: A systematic review and meta-analysis [See comment] [Erratum appears in JAMA 2005 Apr 13;293(14):1728]. JAMA 1724;292:1724-37.
83. Hafner RJ, Watts JM, Rogers J. Quality of life after gastric bypass for morbid obesity. Int J Obes 1991;15:555-60.
84. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-30.
85. Geloneze B, Tambascia MA, Pilla VF, et al. Ghrelin: A gut-brain hormone: Effect of gastric bypass surgery. Obes Surg 2003;13:17-22.
86. Holdstock C, Engstrom BE, Ohrvall M, et al. Ghrelin and adipose tissue regulatory peptides: Effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003;88:3177-83.
87. Williams DL, Grill HJ, Cummings DE, et al. Vagotomy dissociates short- and long-term controls of circulating ghrelin. Endocrinology 2003;144:5184-7.
88. Faraj M, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003;88:1594-602.
89. Hanusch-Enserer U, Brabant G, Roden M. Ghrelin concentrations in morbidly obese patients after adjustable gastric banding [comment]. N Engl J Med 2003;348:2159-60.
90. Leonetti F, Silecchia G, Iacobellis G, et al. Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. J Clin Endocrinol Metab 2003;88:4227-31.
91. Williams DL, Cummings DE, Grill HJ, et al. Meal-related ghrelin suppression requires postgastric feedback. Endocrinology 2003;144:2765-7.
92. Alvarez Bartolome M, Borque M, Martinez-Sarmiento J, et al. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 2002;12:324-7.
93. Kellum JM, Kuemmerle JF, O'Dorisio TM, et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 1990;211:763-70;discussion 770-1.
94. Clements RH, Gonzalez QH, Long CI, et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg 2004;70:1-4;discussion 4-5.